Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Breast Cancer Research and Treatment|April 28, 2021
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimensBeverly Moy, Mafalda Oliveira, Cristina Saura, et al.
The Lancet. Oncology|September 1, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 studySara A Hurvitz, Aditya Bardia, Vanesa Quiroga, et al.
Cell Reports|February 16, 2016
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4Candice Sun Hong, Nicholas A Graham, Wen Gu, et al.
Nature|August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Michael Tsabar, Michael S Cuoco, et al.
The New England Journal of Medicine|March 23, 2022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerJavier Cortés, Sung-Bae Kim, Wei-Pang Chung, et al.
Nature Communications|November 18, 2020
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)Sara A Hurvitz, Jennifer L Caswell-Jin, Katherine L McNamara, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Pageof 14